PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19950900-0	2010	Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis.	DG-051	90-96	leukotriene A4 hydrolase	Homo sapiens	109-133
19950900-4	2010	As applied within the context of LTA(4)H inhibitor design, the chemistry team was able to design a potent compound 20 (DG-051) (K(d) = 26 nM) with high aqueous solubility (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clinical evaluation for the treatment of myocardial infarction and stroke.	DG-051	119-125	leukotriene A4 hydrolase	Homo sapiens	33-40
19819140-0	2009	Synthesis and structural assignment of two major metabolites of the LTA4H inhibitor DG-051.	DG-051	84-90	leukotriene A4 hydrolase	Homo sapiens	68-73